Acute respiratory distress syndrome subphenotypes and therapy responsive traits among preclinical models: protocol for a systematic review and meta-analysis

[1]  D. McAuley,et al.  Corticosteroids in acute respiratory distress syndrome: a step forward, but more evidence is needed. , 2020, The Lancet. Respiratory medicine.

[2]  L. Ware,et al.  Biomarkers and Precision Medicine: State of the Art. , 2020, Critical care clinics.

[3]  Bill B. Chen,et al.  Host-Response Subphenotypes Offer Prognostic Enrichment in Patients With or at Risk for Acute Respiratory Distress Syndrome. , 2019, Critical care medicine.

[4]  C. Seymour,et al.  Murine sepsis phenotypes and differential treatment effects in a randomized trial of prompt antibiotics and fluids , 2019, Critical Care.

[5]  T. van der Poll,et al.  Understanding Heterogeneity in Biological Phenotypes of ARDS by Leukocyte Expression Profiles. , 2019, American journal of respiratory and critical care medicine.

[6]  M. Matthay,et al.  The ex vivo human lung: research value for translational science. , 2019, JCI insight.

[7]  Jeremy C. Weiss,et al.  Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. , 2019, JAMA.

[8]  A. Azim,et al.  Distinct Metabolic Endotype Mirroring Acute Respiratory Distress Syndrome (ARDS) Subphenotype and its Heterogeneous Biology , 2019, Scientific Reports.

[9]  C. Calfee,et al.  Phenotypes in acute respiratory distress syndrome: moving towards precision medicine , 2019, Current opinion in critical care.

[10]  M. Exline,et al.  Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. , 2019, The Lancet. Respiratory medicine.

[11]  Michael A. Matthay,et al.  Acute respiratory distress syndrome , 1996, Nature reviews. Disease primers.

[12]  Kevin L. Delucchi,et al.  Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study , 2018, Intensive Care Medicine.

[13]  V. Sapin,et al.  Inhibition of the Receptor for Advanced Glycation End-Products in Acute Respiratory Distress Syndrome: A Randomised Laboratory Trial in Piglets , 2018, Scientific Reports.

[14]  Qi Hao,et al.  Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E. coli pneumonia , 2018, Thorax.

[15]  J. Laffey,et al.  Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. , 2018, The Lancet. Respiratory medicine.

[16]  M. Ranieri,et al.  Plasma sRAGE is independently associated with increased mortality in ARDS: a meta-analysis of individual patient data , 2018, Intensive Care Medicine.

[17]  V. Sapin,et al.  Recent directions in personalised acute respiratory distress syndrome medicine. , 2017, Anaesthesia, critical care & pain medicine.

[18]  A. Artigas,et al.  Anticoagulant therapy in acute respiratory distress syndrome. , 2018, Annals of translational medicine.

[19]  V. Sapin,et al.  RAGE inhibition reduces acute lung injury in mice , 2017, Scientific Reports.

[20]  J. Laffey,et al.  Fifty Years of Research in ARDS., Insight into Acute Respiratory Distress Syndrome. From Models to Patients , 2017, American journal of respiratory and critical care medicine.

[21]  重川 須賀子,et al.  システマティックレビュー検索式査読のためのガイドライン : PRESS Peer Review of Electronic Search Strategies , 2017 .

[22]  N. Meyer,et al.  Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome , 2017, The Lancet Respiratory Medicine.

[23]  T. van der Poll,et al.  Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis , 2017, Thorax.

[24]  J. Bazin,et al.  Sevoflurane for Sedation in Acute Respiratory Distress Syndrome. A Randomized Controlled Pilot Study , 2016, American journal of respiratory and critical care medicine.

[25]  K. Famous,et al.  Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy , 2016, American journal of respiratory and critical care medicine.

[26]  R. Chambers,et al.  Acute Respiratory Distress Syndrome , 2017, The New England journal of medicine.

[27]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[28]  Derek C Angus,et al.  Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design. , 2016, American journal of respiratory and critical care medicine.

[29]  J. McGowan,et al.  PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. , 2016, Journal of clinical epidemiology.

[30]  A. Zanella,et al.  Personalized medicine for ARDS: the 2035 research agenda , 2016, Intensive Care Medicine.

[31]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[32]  G. Nieman,et al.  ARDS: what experimental models have taught us , 2016, Intensive Care Medicine.

[33]  Anders Larsson,et al.  Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. , 2016, JAMA.

[34]  N. Laird,et al.  Meta-analysis in clinical trials revisited. , 2015, Contemporary clinical trials.

[35]  Kevin Delucchi,et al.  Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. , 2014, The Lancet. Respiratory medicine.

[36]  J. Laffey,et al.  Translational Research in Acute Lung Injury and Pulmonary Fibrosis Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation , 2014 .

[37]  J. Singer,et al.  A Randomized Trial of the Effects of Nebulized Albuterol on Pulmonary Edema in Brain‐Dead Organ Donors , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[38]  I. Douglas,et al.  Erratum: Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury (American Journal of Respiratory and Critical Care Medicine (2011) 184 (561-568)) , 2013 .

[39]  J. Grimshaw,et al.  Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal Experiments , 2013, PLoS medicine.

[40]  Arthur S Slutsky,et al.  Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .

[41]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[42]  Carlijn R Hooijmans,et al.  A search filter for increasing the retrieval of animal studies in Embase , 2011, Laboratory animals.

[43]  Arthur S Slutsky,et al.  An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. , 2011, American journal of respiratory cell and molecular biology.

[44]  Alex John London,et al.  Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty , 2011, PLoS medicine.

[45]  I. Douglas,et al.  Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury. , 2011, American journal of respiratory and critical care medicine.

[46]  M. Matthay,et al.  Mesenchymal stem cells for acute lung injury: preclinical evidence. , 2010, Critical care medicine.

[47]  Carlijn R Hooijmans,et al.  Enhancing search efficiency by means of a search filter for finding all studies on animal experimentation in PubMed , 2010, Laboratory animals.

[48]  I. Cuthill,et al.  Reporting : The ARRIVE Guidelines for Reporting Animal Research , 2010 .

[49]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[50]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[51]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[52]  Jae W. Lee,et al.  Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung , 2009, Proceedings of the National Academy of Sciences.

[53]  T. Martin,et al.  Animal models of acute lung injury , 2008, American journal of physiology. Lung cellular and molecular physiology.

[54]  Joseph Beyene,et al.  The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: A simulation study , 2008 .

[55]  M. Revel,et al.  Comparison of two fluid-management strategies in acute lung injury, H.P. Wiedemann, A.P. Wheeler, G.R. Bernard, B.T. Thompson, D. Hayden, B. deBoisblanc, A.F Jr. Connors, R.D. Hite, A.L. Harabin, in: N Engl J Med, 354. (2006), 2564 , 2007 .

[56]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[57]  S. Chinn.  A simple method for converting an odds ratio to effect size for use in meta-analysis. , 2000, Statistics in medicine.

[58]  Markus Voelter,et al.  State of the Art , 1997, Pediatric Research.